Investor Relations

About Us

American CryoStem Corporation (CRYO) was founded in 2008 and commenced trading on the OTC Markets in 2011. The company has evolved to become a biotechnology pioneer, focusing on standardizing adipose tissue-derived stem cell technologies for the fields of Regenerative and Personalized Medicine meant to help heal and restore function to the human body.

We look forward to helping people live their best lives possible. 

The Company operates a state-of-art, FDA-registered, clinical laboratory in Monmouth Junction, New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking of adipose tissue (fat) and culturing, differentiation of adipose derived stem cells (ADSCs) for use in regenerative medicine.

The Company’s R&D efforts are focused on the discovery, development and commercialization of ADSCs with synergistic partnerships to develop regenerative medicine applications and new intellectual property.


March 11, 2021
American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial
American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial.
February 25, 2021
American CryoStem starts Post-Concussion Syndrome clinical trials
American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement
American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced today that it has entered into an Agreement with BioTherapeutic Labs Corp. (BTL) an FDA registered Umbilical Cord Tissue Manufacturing Company headquartered in Boca Raton, Florida.
January 6, 2021
American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols
American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.

Pipeline Growth Strategy 

We use our patented intellectual property to develop safe and effective cellular medicine products and applications for indications that represent a large unmet need globally. Our therapeutic pipeline of products and applications is based on technologies developed both in-house and obtained through licensing and collaboration arrangements with biotechnology companies.

We intend to utilize our comprehensive cellular platform to support cellular products related to gender, age, nationality, orthopedic applications and disease with partners that can efficiently develop treatments without having to rediscover and recreate the underlying technology for each new product.

INNOVATION

An early adopter of utilizing adipose tissue as a stem cell source we have designed every process and product to standardize, validate and commercialize our platform.

PLATFORM TECHNOLOGY

Patented, modular, platform technology allows complete control of the stem cell processing and manufacturing chain for optimal standardized cellular characteristics.

PATIENT FOCUSED

Allowing a patient to improve their quality of life by easily preparing for their current or future regenerative medicine needs by utilizing our cellular platform with multiple products, (bio-insurance) allowing for usage at every stage of life.

Our Role in the Industry

Regenerative & Personalized Medicine holds the promise of regenerating damaged tissues and organs in the body by stimulating the body’s own repair mechanisms to heal previously irreparable tissues and organs. The industry currently has three major categories where our platform and stem cell products participate;